Skip to main content

Drug Interactions between obeticholic acid and Zegerid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

omeprazole obeticholic acid

Applies to: Zegerid (omeprazole / sodium bicarbonate) and obeticholic acid

Coadministration with obeticholic acid may increase the plasma concentrations of omeprazole. The mechanism of interaction has not been described. Omeprazole is primarily metabolized by CYP450 2C19 and 3A4; however, obeticholic acid is not expected to significantly inhibit these pathways at recommended dosages. When a single 20 mg dose of omeprazole was administered with obeticholic acid 10 mg once daily, omeprazole peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 33% and 32%, respectively. The clinical significance is unknown. Conversely, the AUC of obeticholic acid increased by less than 20%, which is not considered clinically relevant. The effect of omeprazole 40 mg once daily with obeticholic acid 10 mg once daily was not studied.

References

  1. (2016) "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc.

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer